A
Alan C. Sartorelli
Researcher at Yale University
Publications - 537
Citations - 18021
Alan C. Sartorelli is an academic researcher from Yale University. The author has contributed to research in topics: Cellular differentiation & Cell culture. The author has an hindex of 64, co-authored 537 publications receiving 17699 citations. Previous affiliations of Alan C. Sartorelli include University of Nevada, Reno & University of Texas System.
Papers
More filters
Journal Article
Classification of Antineoplastic Agents by their Selective Toxicities toward Oxygenated and Hypoxic Tumor Cells
TL;DR: Future chemotherapeutic regimens for the treatment of solid tumors should include agents and modalities directed toward the hypoxic cell population of the tumor, as well as toward the proliferating and nonproliferating tumor cell compartments.
Journal ArticleDOI
The Leukotriene C4 Transporter MRP1 Regulates CCL19 (MIP-3β, ELC)–Dependent Mobilization of Dendritic Cells to Lymph Nodes
Davide F. Robbiani,Rick Avery Finch,Dirk Jäger,William A. Muller,Alan C. Sartorelli,Gwendalyn J. Randolph +5 more
TL;DR: It is shown that DC migration from skin to lymph nodes utilizes the leukotriene C(4) (LTC(4)) transporter multidrug resistance-associated protein 1 (MRP1), which in turn promotes chemotaxis to CCL19 and mobilization of DCs from the epidermis.
Journal ArticleDOI
Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity
Rick Avery Finch,M.‐C. Liu,Susan P. Grill,William C. Rose,Regina Loomis,Karen M. Vasquez,Yung-Chi Cheng,Alan C. Sartorelli +7 more
TL;DR: The findings demonstrate the superiority of Triapine over hydroxyurea as an anticancer agent and suggest that prevention byTriapine of repair of DNA lesions created by agents that damage DNA may result in efficacious drug combinations for the treatment of cancer.
Journal ArticleDOI
The hypoxic tumor cell: a target for selective cancer chemotherapy.
Journal Article
Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins.
TL;DR: Observations provide evidence that baseline MRP expression protects cells from the toxic effects of xenobiotics by effluxing the xenobiotic and GSH from the intracellular compartment into the extracellular medium by a co-transport mechanism and disruption of the gene encoding MRP abrogates the cotransport of Xenobiotics and G SH.